BioCentury | May 10, 2019
Financial News

New Eisai venture arm to focus on digital tech, dementia, cancer

As Eisai looks to digital technologies for dementia drug discovery, the Japanese pharma’s newly launched venture arm has made its first investment and backed Tokyo-based digital healthcare company Allm. Eisai Co. Ltd. (Tokyo:4523) said the...
BioCentury | Feb 22, 2018
Finance

Bigger BRAIN Initiative

The Brain Research through Advancing Innovative Neurotechnologies (BRAIN) Initiative is preparing to push projects in three areas past the pilot phase with $169 million in new NIH grants announced in 4Q17. The aim is to...
BioCentury | Oct 27, 2014
Company News

Advanced Cell Technology management update

Advanced Cell Technology Inc. (OTCBB:ACTC), Marlborough, Mass. Business: Gene/Cell therapy, Cardiovascular, Ophthalmic Hired: LeRoux Jooste as SVP of business development, a newly created position, and chief commercial officer, formerly SVP and general manager of pharmaceuticals...
BioCentury | Oct 20, 2014
Clinical News

MA09-hRPE cells: Phase I/II data

An open-label, dose-escalation, U.S. Phase I/II trial in 9 dry AMD patients ages >55 who each received sub-retinal transplantation of MA09-hRPE cells in 1 eye showed no adverse safety issues related to the transplanted tissue...
BioCentury | Oct 20, 2014
Clinical News

MA09-hRPE cells: Phase I/II data

An open-label, dose-escalation, U.S. Phase I/II trial in 9 SMD patients ages >18 who received sub-retinal transplantation of MA09-hRPE cells in 1 eye showed no adverse safety issues related to the transplanted tissue and confirmed...
BioCentury | Oct 16, 2014
Clinical News

ACT boosted on stem cell results

Advanced Cell Technology Inc. (OTCBB:ACTC) held most of the gain it picked up ahead of Wednesday's online publication of data from a pair of Phase I/II trials showing visual improvements in patients treated with the...
BioCentury | Sep 1, 2014
Financial News

Advanced Cell Technology financial update

Advanced Cell Technology Inc. (OTCBB:ACTC), Santa Monica, Calif. Business: Gene/Cell therapy, Cardiovascular, Ophthalmic Date announced: 2014-08-27 Note: Advanced Cell Technology implemented a 1-for-100 reverse stock split. Following the split, the company has about 33.6 million...
BioCentury | Jul 14, 2014
Financial News

Advanced Cell Technology financial update

Advanced Cell Technology Inc. (OTCBB:ACTC), Santa Monica, Calif. Business: Gene/Cell therapy, Cardiovascular, Ophthalmic Date announced: 2014-07-03 Note: Advanced Cell entered into a three-year, $30 million stock purchase agreement with Lincoln Park Capital. WIR Staff Cardiovascular...
BioCentury | Jun 30, 2014
Company News

Advanced Cell Technology management update

Advanced Cell Technology Inc. (OTCBB:ACTC), Santa Monica, Calif. Business: Gene/Cell therapy, Cardiovascular, Ophthalmic Hired: Paul Wotton as president and CEO, formerly president and CEO of Antares Pharma Inc. WIR Staff...
BioCentury | Feb 27, 2014
Tools & Techniques

(Pluri)potent acid

Academics and companies alike are scrambling-and thus far failing-to reproduce a surprisingly simple method for generating pluripotent mouse stem cells that uses an external stress stimulus to trigger reprogramming. Whether the method simply does not...
Items per page:
1 - 10 of 108